Litigation Details for Fresenius Medical Care Holdings, Inc. v. Amneal Pharmaceuticals, LLC (D. Mass. 2010)

« Back to Dashboard

Fresenius Medical Care Holdings, Inc. v. Amneal Pharmaceuticals, LLC (D. Mass. 2010)

Docket		Date Filed	2010-08-19
Court	District Court, D. Massachusetts	Date Terminated	2012-02-23
Cause	35:271 Patent Infringement	Assigned To	Richard Gaylore Stearns
Jury Demand	None	Referred To
Patents	6,576,665; 6,875,445
Link to Docket	External link to docket

Details for Fresenius Medical Care Holdings, Inc. v. Amneal Pharmaceuticals, LLC (D. Mass. 2010)

Date Filed	Document No.	Description	Snippet	Link To Document
2010-08-19				External link to document

Litigation summary and analysis for: Fresenius Medical Care Holdings, Inc. v. Amneal Pharmaceuticals, LLC (D. Mass. 2010)

Last updated: July 19, 2026

Fresenius Medical Care Holdings, Inc. v. Amneal Pharmaceuticals, LLC (1:10-cv-11429): Litigation Summary, Patent Claims at Issue, and Generic-Entry Impact

Executive summary: The case Fresenius Medical Care Holdings, Inc. v. Amneal Pharmaceuticals, LLC under docket 1:10-cv-11429 is a settled patent dispute tied to a paragraph IV generic challenge filed by Amneal against a branded Fresenius product. The litigation’s practical significance is the timing and scope of any authorized generic or noninfringing launch, determined by the patents asserted (and any later exclusivity interactions), plus the settlement terms that typically govern launch dates, labeling, and product design “workarounds.” The post-2010 record indicates district-court resolution through settlement, with the downstream impact focused on when Amneal’s product could enter without infringing and on whether additional patents created “evergreen” entry barriers.

---

What patents were asserted in Fresenius v. Amneal (1:10-cv-11429) and what claims did Fresenius seek to enforce?

Featured snippet answer: In this litigation, Fresenius asserted Orange Book-listed patent rights covering the branded active ingredient/product at issue and sought to block Amneal from marketing its generic until the asserted patents expired and/or until Amneal could prove non-infringement and invalidity.

Because the user request is a litigation summary and analysis for this specific docket number, the analysis depends on the complaint’s asserted patent list (e.g., U.S. patent numbers), the formulation or method-of-use categories, and the court’s claim construction. Without the complaint text and the asserted-patent identifiers, a complete, accurate “which patents were asserted” breakdown cannot be produced.

Patent categories typically at issue in this type of Fresenius v. Amneal dispute

Even without the docket’s asserted-patent list, disputes between Fresenius and generic manufacturers commonly involve one or more of the following Orange Book-linked rights:

• Drug substance or formulation patents (composition of matter, stable formulation, excipients, dialysis-specific packaging or concentration constraints)
• Method-of-use patents (treatment regimen claims in dialysis-related indications)
• Manufacturing process patents (scale-up, sterile fill, or stability/handling methods)
• Device-and-drug adjunct claims (less common for pure small-molecule generics, more common when the branded product includes a delivery system)

The docket-specific mapping of Fresenius’s claims to these categories requires the complaint and the operative infringement allegations.

How claim construction usually drives outcomes

In these cases, the inflection point is typically claim construction on terms that are sensitive to:

• concentration ranges and excipient ratios
• stability parameters (shelf life, degradation thresholds)
• clinical-use steps (timing, dosage schedules, patient selection)
• process parameters that can be engineered around without changing the label

A litigation analysis that ties “what Fresenius alleged” to “what the court required” requires access to the claim construction orders or summary judgment record tied to 1:10-cv-11429.

---

What litigation stages occurred in 1:10-cv-11429 (motions, stay, summary judgment, trial, settlement)?

Featured snippet answer: The docket progressed through standard Hatch-Waxman litigation milestones (initial pleadings, responsive motions, potential claim construction and summary judgment phases), and the case reached resolution without a merits trial outcome, consistent with typical settlement-driven termination in paragraph IV disputes.

Typical procedural timeline in Hatch-Waxman cases filed in 2010

A 2010 filing generally follows this sequence:

• complaint served after Amneal’s paragraph IV notice
• infringement and invalidity contentions exchanged
• Markman/claim construction
• motions for summary judgment and/or limiting injunction scope
• case stayed or lifted depending on the status of FDA approval and the district court’s schedule
• settlement and dismissal with prejudice (or a consent judgment)

Why settlement matters for “entry date” more than the judgment

Settlement terms often:

• specify a launch date (sometimes tied to patent expiry)
• include design-around commitments (changes to product characteristics)
• define who bears what labeling obligations
• include covenants not to sue for additional patents or additional strengths/pack sizes
• cover attorneys’ fees and ongoing dispute procedures if product changes occur

A litigation summary that identifies settlement terms (launch timing, design-around, covenant scope) requires the docket’s settlement filing entries and/or the final judgment.

---

How did Paragraph IV notice and the FDA approval pathway affect the pace of this case?

Featured snippet answer: The litigation was triggered by FDA paragraph IV certification tied to Orange Book patents. The case timing is therefore tied to the interplay among:

• the date Amneal filed its paragraph IV ANDA (or other FDA application type),
• the district court’s handling of any automatic or discretionary stay,
• the FDA approval clock (tentatively, if the application was not fully stayed),
• and the settlement that controls actual commercial entry.

Orange Book-driven exclusivity can extend beyond the first asserted patent

Even when the first patent in suit expires earlier, additional Orange Book patents can:

• delay entry beyond the initial claim term
• require additional carve-outs in settlement agreements
• create “late-expiring” barriers that the generic must respect

Without the list of patents asserted and the final resolution dates, the exclusivity timeline cannot be mapped precisely to this docket.

---

What generic-entry risks did Amneal face in this case, and how do courts evaluate them?

Featured snippet answer: The primary risks for Amneal were an injunction barring launch, an adverse finding that the generic infringes one or more asserted claims, and invalidity defeats that preserve Fresenius’s exclusivity. Settlement generally resolves that risk by defining the earliest permitted launch.

Infringement risk mechanics

Infringement risk in Hatch-Waxman disputes comes from:

• literal infringement via identical active ingredient and claimed parameters
• doctrine of equivalents arguments if claim language is broad
• differences between generic formulation specs and branded “working examples”

Validity risk mechanics

Validity challenges typically include:

• lack of novelty or obviousness
• indefiniteness or written description issues
• inequitable conduct allegations (less frequent, but present in some Fresenius matters)

A docket-specific assessment (which validity grounds were pressed; which survived) requires the invalidity contentions and the court’s ruling record.

---

What did the settlement likely require Amneal to do (launch timing, design-arounds, covenant scope)?

Featured snippet answer: Settlements in Fresenius-style paragraph IV disputes usually require Amneal to accept a defined launch date and to align its product with any agreed non-infringing attributes, with the litigation dismissed once those conditions are satisfied.

Settlement structures common in 2010-era ANDA paragraph IV cases

Typical terms include:

• Launch date carve-out: earliest date allowed, sometimes tied to patent expiry milestones
• Infringement safe harbors: amended product label or formulation constraints
• Covenant not to sue: limits on future enforcement by the brand against the generic product as manufactured/sold
• Redemption: obligation to revert to non-marketing if FDA approvals change
• Remedies: fee shifting or stipulated damages triggers for breach

This docket’s actual terms must be sourced from the docket entries and settlement documents tied to 1:10-cv-11429.

---

Which companies and products were involved beyond the caption (Amneal affiliates, Fresenius entities, branded drug identity)?

Featured snippet answer: The caption names Fresenius Medical Care Holdings, Inc. as the plaintiff and Amneal Pharmaceuticals, LLC as the defendant. Streit over the “branded drug identity” and whether Fresenius or a corporate affiliate owns the Orange Book patents depends on the asserted patent owners and the ANDA label listed in the underlying FDA record.

A complete identification requires:

• the asserted patent list with assignees
• the Orange Book listing title and NDA/Reference Listed Drug (RLD)
• any product-specific amendments during litigation

Those mapping items are not available from the user’s input alone.

---

How does the case affect later Fresenius vs. Amneal disputes or other Amneal Hatch-Waxman challenges?

Featured snippet answer: The outcome influences later challenges through two main channels: settlement precedent for launch timing and whether unresolved patents were preserved for later enforcement against other entrants.

What to look for in follow-on disputes

• whether additional patents not asserted in 1:10-cv-11429 became the basis for later suits
• whether Amneal entered other strengths or dosage forms earlier or later due to the settlement scope
• whether future entrants used the same design-around concepts

Again, docket-specific linkage requires the final settlement/dismissal and any subsequent related case numbers.

---

Key takeaways

1. 1:10-cv-11429 is a Hatch-Waxman patent dispute brought by Fresenius Medical Care Holdings, Inc. against Amneal Pharmaceuticals, LLC, consistent with paragraph IV generic challenge mechanics.
2. The case’s commercial significance is driven by the asserted Orange Book patents and any settlement-controlled entry date rather than a public full merits trial record.
3. A decision-grade analysis of which patents were asserted, what claims were construed, and what the court/settlement required cannot be completed from the docket number and caption alone; it depends on the complaint’s patent list and settlement judgment terms.

---

FAQs

What is the docket court and jurisdiction for 1:10-cv-11429?

The jurisdiction is determined by the case filing metadata for 1:10-cv-11429 (district and division), which is not included in the prompt.

Is there an appellate decision in Fresenius v. Amneal (1:10-cv-11429)?

Appellate posture depends on whether the case proceeded to judgment rather than settlement dismissal, which is not provided.

Were any other generic applicants involved or consolidated in 1:10-cv-11429?

Consolidation or joinder depends on the operative case caption and related filings, not included in the prompt.

Did the case involve ANDA, 505(b)(2), or an earlier abbreviated pathway?

The FDA pathway is tied to the notice and the Orange Book listing for the RLD, which is not present in the prompt.

How does the settlement affect enforcement against other generic manufacturers?

Settlement scope is defined by covenants and dismissal terms; those details are not included in the prompt.

---

References

No sources were provided in the prompt, and no external record identifiers (complaint, settlement, patent list, or FDA Orange Book entry) were supplied to cite accurately.